Multiple trials are exploring the use of immune-checkpoints inhibitors in TNBC (A-brave, NCT02954874, KEYNOTE-522) and CDK4/6 inhibitors in hormone receptor-positive BC (Monarch-e). Here, CDK4 is linked to breast cancer.